Review
doi: 10.1111/ddg.15020.
New therapeutic developments for basal cell carcinoma
Affiliations
- PMID: 37070499
- DOI: 10.1111/ddg.15020
Item in Clipboard
Review
New therapeutic developments for basal cell carcinoma
J Dtsch Dermatol Ges.
2023 Apr.
Abstract
In 2013, systemic therapy was introduced into the treatment of locally advanced (laBCC) and metastatic basal cell carcinoma (mBCC). Meanwhile, immunotherapy has been approved in this indication as well. Additional immunotherapies and other classes of drugs including combination regimens are currently being investigated in clinical trials. These agents might considerably expand the therapeutic armamentarium for laBCC and mBCC in the future.
© 2023 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Similar articles
-
Cemiplimab in the treatment of metastatic basal cell carcinoma.Future Oncol. 2025 Jul;21(16):1999-2005. doi: 10.1080/14796694.2025.2511568. Epub 2025 May 27. Future Oncol. 2025. PMID: 40432222 Review.
-
Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.JAMA Dermatol. 2016 Jul 1;152(7):816-24. doi: 10.1001/jamadermatol.2016.0780. JAMA Dermatol. 2016. PMID: 27096888
-
Systemic treatments for metastatic cutaneous melanoma.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article.
-
Interventions for basal cell carcinoma of the skin.Cochrane Database Syst Rev. 2003;(2):CD003412. doi: 10.1002/14651858.CD003412. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003412. doi: 10.1002/14651858.CD003412.pub2. PMID: 12804465 Updated.
-
Interventions for basal cell carcinoma of the skin.Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003412. doi: 10.1002/14651858.CD003412.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2020 Nov 17;11:CD003412. doi: 10.1002/14651858.CD003412.pub3. PMID: 17253489 Updated.
References
REFERENCES
-
- Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer. 2019;118:10-34.
-
- Herm F, Basset-Séguin N. Emerging drugs for the treatment of basal cell carcinoma. Exp Opin Emerging Drugs. 2021;1:17-25.
-
- Matas-Nadal C, Sagristà M, Gómez-Arbonés X, et al. Risk factors for early-onset basal cell carcinomas and the trend towards their female predominance. J Dtsch Dermatol Ges. 2021;19(3):364-371.
-
- Seidl-Philipp M, Frischhut N, Höllweger N, et al. Known and new facts on basal cell carcinoma. J Dtsch Dermatol Ges. 2021;19(7):1021-1041.
-
- Lang BM, Balermpas P, Bauer A, et al. S2k guidelines for cutaneous basal cell carcinoma - part 1: epidemiology, genetics and diagnosis. J Dtsch Dermatol Ges. 2019;17(1):94-103.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
